Investigation of pulmonary epithelial permeability in patients after hyperbaric oxygen therapy by 99mTc diethylenetriaminepentaacetic acid aerosol inhalation lung scintigraphy.
The aim of this study was to evaluate the possibility of pulmonary epithelial permeability damage in patients after hyperbaric oxygen therapy (HBOT) by 99mTc diethylenetriaminepentaacetic acid (99mTc-DTPA) aerosol inhalation lung scintigraphy. Twenty-five controls and 21 patients with normal chest X-rays and no cigarette smoking for at least 1 year were recruited for the study. 99mTc-DTPA aerosol inhalation lung scans were performed after 20 HBOT sessions in 21 patients with refractory osteomyelitis or diabetic foot. The HBOT with 100% oxygen at 2.5 atm absolute for 100 min was performed five times a week. Clearance rates (%/min) of 99mTc-DTPA aerosol in each lung field were calculated from the dynamic images for 30 min. Clearance rates of 99mTc-DTPA aerosol were compared between patients and controls by the unpaired t test. Thirteen patients who had 99mTc-DTPA aerosol lung scans before and after HBOT therapy studies were tested for statistical significance by using the paired t test. There was no statistically significant difference (P>0.05, unpaired t test) between patients and controls in every lung field. For the 13 patients who had 99mTc-DTPA aerosol studies both before and after 20 HBOT sessions, the results also showed no statistically significant difference (P>0.05, paired t test). It is concluded that there was no demonstrable pulmonary epithelial permeability change under current clinical HBOT protocol.
Chang
Y-C
YC
Department of Nuclear Medicine, Chang Gung Memorial Hospital and Chang Gung University, Taoyuan, Taiwan.
Kao
P-F
PF
Lee
M S
MS
Lin
M-C
MC
Tzen
K-Y
KY
D000280:Administration, Inhalation; D000328:Adult; D000336:Aerosols; D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D006801:Humans; D006931:Hyperbaric Oxygenation / Q000009:adverse effects*; D008171:Lung Diseases / Q000000981:diagnostic imaging* / Q000209:etiology* / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D010539:Permeability; D011446:Prospective Studies; D011877:Radionuclide Imaging / Q000379:methods; D019275:Radiopharmaceuticals / Q000493:pharmacokinetics; D020545:Respiratory Mucosa / Q000378:metabolism* / Q000503:physiopathology; D016284:Technetium Tc 99m Pentetate / Q000008:administration & dosage / Q000493:pharmacokinetics*
D000336:Aerosols; D019275:Radiopharmaceuticals; D016284:Technetium Tc 99m Pentetate